儿童哮吼合并COVID-19
本文描述3例既往健康儿童(11月龄、2岁、9岁)从急诊收入独立儿童医院,为首次记录以哮吼为SARS-CoV-2感染表现的病例。3例均以非特异性上呼吸道症状起病,发展为犬吠样咳嗽伴静息性喘鸣和呼吸窘迫;鼻咽拭子PCR确诊SARS-CoV-2,其他病原包括常见哮吼病因均阴性。每例接受≥3次雾化消旋肾上腺素,用药后短期几乎无改善;静息性喘鸣缓解时间长达13、19、21小时;均早期接受地塞米松并全部住院,每例因症状持续时间长额外接受至少1次地塞米松(在本院属非典型治疗);1例需氦氧混合气治疗并收入重症监护。作者认为该新描述的COVID-19哮吼可表现为显著病理改变,可能不如典型哮吼恢复快。
要点
- 3例既往健康儿童(11月龄、2岁、9岁)以哮吼为SARS-CoV-2感染表现,均出现犬吠样咳嗽、静息性喘鸣和呼吸窘迫。
- 每例接受≥3次雾化消旋肾上腺素后短期几乎无改善,静息性喘鸣缓解时间分别为13、19、21小时。
- 3例均早期接受地塞米松并住院,每例因症状持续时间长额外接受至少1次地塞米松(在本院属非典型治疗)。
- 1例需氦氧混合气治疗并收入重症监护,全部患儿最终出院。
- 作者认为:常规哮吼不查病原,但COVID-19哮吼有预后和隔离意义,应考虑检测SARS-CoV-2。
适用人群与场景
- 3例既往健康儿童,年龄分别为11月龄、2岁、9岁,从急诊收入独立儿童医院。
- 以非特异性上呼吸道症状起病,发展为犬吠样咳嗽伴静息性喘鸣和呼吸窘迫的哮吼表现。
处置流程与药物剂量
- 3例均接受≥3次雾化消旋肾上腺素,用药后短期几乎无改善。
- 3例均早期接受地塞米松并全部住院,每例因症状持续时间长额外接受至少1次地塞米松(在本院属非典型治疗)。
- 1例需氦氧混合气治疗并收入重症监护。
红旗征与不能漏的情况
- 静息性喘鸣持续13、19、21小时,提示COVID-19哮吼可能不如典型哮吼恢复快。
- 接受≥3次雾化消旋肾上腺素后短期几乎无改善,提示需警惕迁延病程。
研究设计与关键结果
- 本文为病例系列,描述3例既往健康儿童以哮吼为SARS-CoV-2感染表现,鼻咽拭子PCR确诊SARS-CoV-2,其他病原包括常见哮吼病因均阴性。
- 3例均接受≥3次雾化消旋肾上腺素后短期几乎无改善,静息性喘鸣缓解时间分别为13、19、21小时。
- 3例均早期接受地塞米松并住院,每例额外接受至少1次地塞米松(在本院属非典型治疗);1例需氦氧混合气治疗并收入重症监护;全部患儿最终出院。
证据类型、等级与局限
- 证据类型:病例系列(3例)。
- 局限:作者称其为有限的经验(our limited experience),并认为该新描述的COVID-19哮吼可表现为显著病理改变、可能不如典型哮吼恢复快。
对床旁实践的改变
- 作者认为:常规哮吼不查病原,但面对COVID-19哮吼应考虑检测SARS-CoV-2,因其有预后意义和延长隔离的意义。
- 作者认为:COVID-19哮吼可表现为显著病理改变,可能不如典型哮吼恢复快。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
We describe three previously healthy children, admitted from our emergency department (ED) to our free-standing children's hospital, as the first documented cases of croup as a manifestation of SARS-CoV-2 infection. All three cases (ages 11 months, 2 years, and 9 years old) presented with non-specific upper-respiratory-tract symptoms that developed into a barky cough with associated stridor at rest and respiratory distress. All were diagnosed with SARS-CoV-2 by polymerase chain reaction testing from nasopharyngeal samples that were negative for all other pathogens including the most common etiologies for croup. Each received multiple (≥3) doses of nebulized racemic epinephrine with minimal to no improvement shortly after medication. All had a prolonged period of time from ED presentation until the resolution of their stridor at rest (13, 19, and 21 h). All received dexamethasone early in their ED treatment and all were admitted. All three received at least one additional dose of dexamethasone, an atypical treatment occurrence in our hospital, due to each patient's prolonged duration of symptoms. One child required heliox therapy and admission to intensive care. All patients were eventually discharged. Pathogen testing is usually not indicated in croup, but with "COVID-19 croup," SARS-CoV-2 testing should be considered given the prognostic significance and prolonged quarantine implications. Our limited experience with this newly described COVID-19 croup condition suggests that cases can present with significant pathology and might not improve as rapidly as those with typical croup.
参考来源
- Venn AMR, Schmidt JM, Mullan PC, et al. Pediatric croup with COVID-19. Am J Emerg Med. 2020. PMID: 32980228. doi:10.1016/j.ajem.2020.09.034
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。